{"title":"Drug Immunogenicity","description":null,"products":[{"product_id":"human-ada-adenosine-deaminase-elisa-kit-picokine-bhe21001058","title":"Human ADA\/Adenosine Deaminase ELISA Kit PicoKine®","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAlso known as:\u003c\/strong\u003e Adenosine deaminase, 3.5.4.4, Adenosine aminohydrolase, ADA, ADA1.\u003c\/p\u003e\u003cp\u003eHuman \u003cstrong\u003eADA\/Adenosine Deaminase\u003c\/strong\u003e (\u003cstrong\u003eADA\u003c\/strong\u003e) is a commonly measured biological analyte that can provide insight into cellular state and tissue physiology. This target is frequently investigated in \u003cstrong\u003eMolecular \u0026amp; Cellular Biology\u003c\/strong\u003e research contexts. As with many protein targets, abundance can be influenced by transcriptional regulation, secretion or shedding, proteolytic processing, and clearance. Quantitative measurement is often used to connect molecular changes with phenotypes such as stress responses, immune activation, differentiation, or tissue remodeling.\u003c\/p\u003e\u003ch2\u003eBiological context and interpretation\u003c\/h2\u003e\u003cp\u003eProtein-level readouts complement nucleic-acid measurements by reflecting post-transcriptional control and protein stability. Depending on the model system, changes may be transient or sustained, and may represent direct pathway engagement or secondary effects. When interpreting results, consider sample matrix effects, timing relative to stimulation or treatment, and whether complexes or modified forms of the analyte may be present.\u003c\/p\u003e\u003ch2\u003eWhy it matters in research\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparative quantification:\u003c\/strong\u003e Supports analysis across experimental groups, time points, or dose ranges.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePathway context:\u003c\/strong\u003e Useful as part of a broader marker panel to triangulate biological mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel characterization:\u003c\/strong\u003e Helps profile baseline vs perturbed states in cells, tissues, or biofluids.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eRelated pathways and interacting partners\u003c\/h2\u003e\u003cp\u003eFor many targets, interpretability improves when measured alongside biologically connected markers (e.g., upstream regulators, downstream effectors, and cell-type indicators). Designing panels around a pathway hypothesis can help distinguish primary pathway activation from general stress or inflammation.\u003c\/p\u003e","brand":"Boster Bio","offers":[{"title":"96 wells\/kit, with removable strips.","offer_id":52920845500781,"sku":"EK1446","price":513.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ek1446_86ed42c8-4af6-4ded-9123-c251679e7df5.png?v=1769078012"},{"product_id":"human-adenosine-deaminase-ada-elisa-kit-bhe12102456","title":"Human Adenosine Deaminase, ADA ELISA Kit","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAdenosine Deaminase (ADA)\u003c\/strong\u003e is a molecular target commonly studied in epigenetics and nuclear signaling research. This molecule is commonly investigated as part of broader signaling, regulatory, or homeostatic networks.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUniProt\u003c\/strong\u003e: P00813\u003c\/p\u003e\u003ch2\u003eBiological role and pathway context\u003c\/h2\u003e\u003cp\u003eIn the literature, Adenosine Deaminase (ADA) is frequently examined in relation to mechanistic biology studies, biomarker-focused profiling, and disease-model research. Depending on the model system, changes in abundance can be associated with shifts in signaling state, cellular composition, or tissue physiology.\u003c\/p\u003e\u003ch2\u003eExpression and regulation\u003c\/h2\u003e\u003cp\u003eExpression of Adenosine Deaminase (ADA) can vary across tissues and cell types and may change under conditions such as immune activation, stress responses, injury, infection, or metabolic perturbation. Reported regulation may involve transcriptional control as well as post-translational processes that influence stability, localization, processing, or secretion.\u003c\/p\u003e\u003ch2\u003eResearch and disease relevance\u003c\/h2\u003e\u003cp\u003eAdenosine Deaminase (ADA) has been reported as a useful readout in studies of physiological regulation and disease-associated processes. These observations make it relevant for hypothesis-driven research and biomarker exploration, while interpretation should remain grounded in the specific species, sample matrix, and study design.\u003c\/p\u003e\u003ch2\u003eInterpreting concentration measurements\u003c\/h2\u003e\u003cp\u003eMeasured levels of Adenosine Deaminase (ADA) can reflect multiple biological factors, including production rate, turnover, compartmental distribution, and sample composition. As a result, conclusions are often supported by considering broader pathway context and complementary readouts rather than relying on a single analyte alone.\u003c\/p\u003e\u003ch2\u003eNomenclature\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAdenosine Deaminase (ADA)\u003c\/strong\u003e may also be referred to as \u003cstrong\u003eADA\u003c\/strong\u003e, \u003cstrong\u003eAdenosine aminohydrolase\u003c\/strong\u003e, and \u003cstrong\u003eAdenosine deaminase\u003c\/strong\u003e in publications and databases. Nomenclature differences and species context can influence how results are compared across studies.\u003c\/p\u003e","brand":"Bioassay Technology Laboratory","offers":[{"title":"96T","offer_id":52952462262637,"sku":"E0777Hu-96T","price":458.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/E0777Hu.jpg?v=1769146080"},{"product_id":"mouse-adenosine-deaminase-ada-elisa-kit-bhe12109442","title":"Mouse Adenosine Deaminase, ADA ELISA Kit","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAdenosine Deaminase (ADA)\u003c\/strong\u003e is a molecular target commonly studied in epigenetics and nuclear signaling research. This molecule is commonly investigated as part of broader signaling, regulatory, or homeostatic networks.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUniProt\u003c\/strong\u003e: P03958\u003c\/p\u003e\u003ch2\u003eBiological role and pathway context\u003c\/h2\u003e\u003cp\u003eIn the literature, Adenosine Deaminase (ADA) is frequently examined in relation to mechanistic biology studies, biomarker-focused profiling, and disease-model research. Depending on the model system, changes in abundance can be associated with shifts in signaling state, cellular composition, or tissue physiology.\u003c\/p\u003e\u003ch2\u003eExpression and regulation\u003c\/h2\u003e\u003cp\u003eExpression of Adenosine Deaminase (ADA) can vary across tissues and cell types and may change under conditions such as immune activation, stress responses, injury, infection, or metabolic perturbation. Reported regulation may involve transcriptional control as well as post-translational processes that influence stability, localization, processing, or secretion.\u003c\/p\u003e\u003ch2\u003eResearch and disease relevance\u003c\/h2\u003e\u003cp\u003eAdenosine Deaminase (ADA) has been reported as a useful readout in studies of physiological regulation and disease-associated processes. These observations make it relevant for hypothesis-driven research and biomarker exploration, while interpretation should remain grounded in the specific species, sample matrix, and study design.\u003c\/p\u003e\u003ch2\u003eInterpreting concentration measurements\u003c\/h2\u003e\u003cp\u003eMeasured levels of Adenosine Deaminase (ADA) can reflect multiple biological factors, including production rate, turnover, compartmental distribution, and sample composition. As a result, conclusions are often supported by considering broader pathway context and complementary readouts rather than relying on a single analyte alone.\u003c\/p\u003e\u003ch2\u003eNomenclature\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eAdenosine Deaminase (ADA)\u003c\/strong\u003e may also be referred to as \u003cstrong\u003eADA\u003c\/strong\u003e, \u003cstrong\u003eAdenosine aminohydrolase\u003c\/strong\u003e, and \u003cstrong\u003eAdenosine deaminase\u003c\/strong\u003e in publications and databases. Nomenclature differences and species context can influence how results are compared across studies.\u003c\/p\u003e","brand":"Bioassay Technology Laboratory","offers":[{"title":"96T","offer_id":52952626725229,"sku":"E1600Mo-96T","price":458.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/E1600Mo.jpg?v=1769147093"},{"product_id":"rat-ada-adenosine-deaminase-elisa-kit-bhe152011205","title":"Rat ADA(Adenosine Deaminase) ELISA Kit","description":"\u003ch3\u003eScientific background\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e is a biologically relevant protein marker measured to support mechanistic studies and biomarker discovery (context dependent).\u003c\/p\u003e\u003cp\u003eProtein concentrations can change due to secretion, degradation, cell composition shifts, or post-transcriptional regulation, so ELISA readouts often add information beyond gene expression alone.\u003c\/p\u003e\u003cp\u003eQuantitative measurements help compare groups and time points using standardized curves and can be interpreted alongside phenotype and pathway-specific readouts.\u003c\/p\u003e\u003ch3\u003eWhy it matters\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eQuantify \u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e to compare biological changes across conditions, doses, or time points.\u003c\/li\u003e\n\u003cli\u003eGenerate concentration data from a standard curve to support biomarker and mechanistic studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow the ELISA works\u003c\/h3\u003e\u003cp\u003eDesigned for \u003cstrong\u003eRat\u003c\/strong\u003e samples, this kit uses a \u003cstrong\u003eThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat ADA. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat ADA. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat ADA, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat ADA in the samples is then determined by comparing the OD of the samples to the standard curve.\u003c\/strong\u003e. After binding and washing, signal is converted to concentration using a standard curve.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSample types\u003c\/strong\u003e: Serum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection range\u003c\/strong\u003e: 0.16-10 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSensitivity\/LoD\u003c\/strong\u003e: 0.071 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay time\u003c\/strong\u003e: 3.5h\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"ELK Biotechnology","offers":[{"title":"96 T","offer_id":52964646912365,"sku":"ELK9467-96T","price":595.4,"currency_code":"USD","in_stock":true},{"title":"48 T","offer_id":52964646945133,"sku":"ELK9467-48T","price":416.0,"currency_code":"USD","in_stock":true},{"title":"96 T X 5","offer_id":52964646977901,"sku":"ELK9467-96TX5","price":2531.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/1h1qbq4v21p4717oo1b_daf9c04c-4278-4452-8b74-cc93e6d0e6a5.jpg?v=1771841199"},{"product_id":"horse-ada-adenosine-deaminase-elisa-kit-bhe152011565","title":"Horse ADA(Adenosine Deaminase) ELISA Kit","description":"\u003ch3\u003eScientific background\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e is a biologically relevant protein marker measured to support mechanistic studies and biomarker discovery (context dependent).\u003c\/p\u003e\u003cp\u003eProtein concentrations can change due to secretion, degradation, cell composition shifts, or post-transcriptional regulation, so ELISA readouts often add information beyond gene expression alone.\u003c\/p\u003e\u003cp\u003eQuantitative measurements help compare groups and time points using standardized curves and can be interpreted alongside phenotype and pathway-specific readouts.\u003c\/p\u003e\u003ch3\u003eWhy it matters\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eQuantify \u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e to compare biological changes across conditions, doses, or time points.\u003c\/li\u003e\n\u003cli\u003eGenerate concentration data from a standard curve to support biomarker and mechanistic studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow the ELISA works\u003c\/h3\u003e\u003cp\u003eDesigned for \u003cstrong\u003eHorse\u003c\/strong\u003e samples, this kit uses a \u003cstrong\u003eThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Horse ADA. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Horse ADA. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Horse ADA, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Horse ADA in the samples is then determined by comparing the OD of the samples to the standard curve.\u003c\/strong\u003e. After binding and washing, signal is converted to concentration using a standard curve.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSample types\u003c\/strong\u003e: Serum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection range\u003c\/strong\u003e: 0.16-10 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSensitivity\/LoD\u003c\/strong\u003e: 0.068 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay time\u003c\/strong\u003e: 3.5h\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"ELK Biotechnology","offers":[{"title":"96 T","offer_id":52964686528877,"sku":"ELK9823-96T","price":595.4,"currency_code":"USD","in_stock":true},{"title":"48 T","offer_id":52964686561645,"sku":"ELK9823-48T","price":416.0,"currency_code":"USD","in_stock":true},{"title":"96 T X 5","offer_id":52964686594413,"sku":"ELK9823-96TX5","price":2531.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/1h1qbq4v21p4717oo1b_200954ff-7fd6-46f2-9522-4d0f1bcc6dfd.jpg?v=1771841445"},{"product_id":"human-ada-adenosine-deaminase-elisa-kit-bhe15203756","title":"Human ADA(Adenosine Deaminase) ELISA Kit","description":"\u003ch3\u003eScientific background\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e is a biologically relevant protein marker measured to support mechanistic studies and biomarker discovery (context dependent).\u003c\/p\u003e\u003cp\u003eProtein concentrations can change due to secretion, degradation, cell composition shifts, or post-transcriptional regulation, so ELISA readouts often add information beyond gene expression alone.\u003c\/p\u003e\u003cp\u003eQuantitative measurements help compare groups and time points using standardized curves and can be interpreted alongside phenotype and pathway-specific readouts.\u003c\/p\u003e\u003ch3\u003eWhy it matters\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eQuantify \u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e to compare biological changes across conditions, doses, or time points.\u003c\/li\u003e\n\u003cli\u003eGenerate concentration data from a standard curve to support biomarker and mechanistic studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow the ELISA works\u003c\/h3\u003e\u003cp\u003eDesigned for \u003cstrong\u003eHuman\u003c\/strong\u003e samples, this kit uses a \u003cstrong\u003eThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human ADA. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human ADA. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human ADA, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human ADA in the samples is then determined by comparing the OD of the samples to the standard curve.\u003c\/strong\u003e. After binding and washing, signal is converted to concentration using a standard curve.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSample types\u003c\/strong\u003e: Serum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection range\u003c\/strong\u003e: 0.16-10 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSensitivity\/LoD\u003c\/strong\u003e: 0.066 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay time\u003c\/strong\u003e: 3.5h\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"ELK Biotechnology","offers":[{"title":"96 T","offer_id":52965379604845,"sku":"ELK1970-96T","price":595.4,"currency_code":"USD","in_stock":true},{"title":"48 T","offer_id":52965379637613,"sku":"ELK1970-48T","price":416.0,"currency_code":"USD","in_stock":true},{"title":"96 T X 5","offer_id":52965379670381,"sku":"ELK1970-96TX5","price":2531.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/1h1qbq4v21p4717oo1b_e7f8e256-4bc8-47ca-9b37-886f3a517330.jpg?v=1771843110"},{"product_id":"chicken-ada-adenosine-deaminase-elisa-kit-bhe15207908","title":"Chicken ADA(Adenosine Deaminase) ELISA Kit","description":"\u003ch3\u003eScientific background\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e is a biologically relevant protein marker measured to support mechanistic studies and biomarker discovery (context dependent).\u003c\/p\u003e\u003cp\u003eProtein concentrations can change due to secretion, degradation, cell composition shifts, or post-transcriptional regulation, so ELISA readouts often add information beyond gene expression alone.\u003c\/p\u003e\u003cp\u003eQuantitative measurements help compare groups and time points using standardized curves and can be interpreted alongside phenotype and pathway-specific readouts.\u003c\/p\u003e\u003ch3\u003eWhy it matters\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eQuantify \u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e to compare biological changes across conditions, doses, or time points.\u003c\/li\u003e\n\u003cli\u003eGenerate concentration data from a standard curve to support biomarker and mechanistic studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow the ELISA works\u003c\/h3\u003e\u003cp\u003eDesigned for \u003cstrong\u003eChicken\u003c\/strong\u003e samples, this kit uses a \u003cstrong\u003eThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Chicken ADA. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Chicken ADA. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Chicken ADA, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Chicken ADA in the samples is then determined by comparing the OD of the samples to the standard curve.\u003c\/strong\u003e. After binding and washing, signal is converted to concentration using a standard curve.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSample types\u003c\/strong\u003e: Serum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection range\u003c\/strong\u003e: 0.16-10 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSensitivity\/LoD\u003c\/strong\u003e: 0.067 ng\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay time\u003c\/strong\u003e: 3.5h\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"ELK Biotechnology","offers":[{"title":"96 T","offer_id":52965907628397,"sku":"ELK8740-96T","price":595.4,"currency_code":"USD","in_stock":true},{"title":"48 T","offer_id":52965907661165,"sku":"ELK8740-48T","price":416.0,"currency_code":"USD","in_stock":true},{"title":"96 T X 5","offer_id":52965907693933,"sku":"ELK8740-96TX5","price":2531.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/1h1qbq4v21p4717oo1b_6d175d3d-2e81-4f59-90ef-605237e1db27.jpg?v=1771845287"},{"product_id":"mouse-ada-adenosine-deaminase-elisa-kit-bhe15210421","title":"Mouse ADA(Adenosine Deaminase) ELISA Kit","description":"\u003ch3\u003eScientific background\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e is a biologically relevant protein marker measured to support mechanistic studies and biomarker discovery (context dependent).\u003c\/p\u003e\u003cp\u003eProtein concentrations can change due to secretion, degradation, cell composition shifts, or post-transcriptional regulation, so ELISA readouts often add information beyond gene expression alone.\u003c\/p\u003e\u003cp\u003eQuantitative measurements help compare groups and time points using standardized curves and can be interpreted alongside phenotype and pathway-specific readouts.\u003c\/p\u003e\u003ch3\u003eWhy it matters\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eQuantify \u003cstrong\u003eADA (Adenosine Deaminase)\u003c\/strong\u003e to compare biological changes across conditions, doses, or time points.\u003c\/li\u003e\n\u003cli\u003eGenerate concentration data from a standard curve to support biomarker and mechanistic studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow the ELISA works\u003c\/h3\u003e\u003cp\u003eDesigned for \u003cstrong\u003eMouse\u003c\/strong\u003e samples, this kit uses a \u003cstrong\u003eThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse ADA. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse ADA. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse ADA, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse ADA in the samples is then determined by comparing the OD of the samples to the standard curve.\u003c\/strong\u003e. After binding and washing, signal is converted to concentration using a standard curve.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSample types\u003c\/strong\u003e: Serum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDetection range\u003c\/strong\u003e: 78.13-5000 pg\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSensitivity\/LoD\u003c\/strong\u003e: 19.36 pg\/mL\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay time\u003c\/strong\u003e: 3.5h\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"ELK Biotechnology","offers":[{"title":"96 T","offer_id":52966198477165,"sku":"ELK9943-96T","price":595.4,"currency_code":"USD","in_stock":true},{"title":"48 T","offer_id":52966198509933,"sku":"ELK9943-48T","price":416.0,"currency_code":"USD","in_stock":true},{"title":"96 T X 5","offer_id":52966198542701,"sku":"ELK9943-96TX5","price":2531.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/1h1qbq4v21p4717oo1b_a2e76d7c-8b23-4f33-9489-0053c6900a85.jpg?v=1771846645"},{"product_id":"recombinant-mouse-ada-adenosine-deaminase-protein-n-his-bhp21402077","title":"Recombinant Mouse ADA\/Adenosine deaminase Protein, N-His","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eTarget identity:\u003c\/strong\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is a protein. It is typically cell-type and isoform dependent (intracellular or extracellular).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is provided as a recombinant protein reagent for \u003cstrong\u003eresearch use only\u003c\/strong\u003e. Recombinant proteins are commonly used as defined molecular inputs in biochemical and cell-free systems, enabling controlled interrogation of binding, activity, and pathway-relevant interactions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eProtein identity context:\u003c\/strong\u003e ADA (expression region Met1-Gln352; approx. molecular weight 42.14 kDa).\u003c\/p\u003e\u003ch2\u003eBiological significance and function\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is used in RUO research to interrogate molecular mechanisms, interaction networks, and pathway-linked phenotypes in experimental systems. This target is frequently explored in \u003cstrong\u003eMolecular \u0026amp; Cellular Biology\u003c\/strong\u003e research contexts.\u003c\/p\u003e\u003ch2\u003eMolecular characteristics\u003c\/h2\u003e\u003cp\u003eKey molecular attributes can influence binding behavior, stability, and assay background—especially for multimeric, disulfide-rich, or PTM-dependent targets.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e Met1-Gln352\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 42.14 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003ePost-translational considerations:\u003c\/strong\u003e Prokaryotic expression typically yields a non-glycosylated recombinant form. This is often appropriate for many intracellular proteins and binding studies, while disulfide-rich or PTM-dependent extracellular targets may behave differently when native PTMs are required.\u003c\/p\u003e\u003ch2\u003eExpression and purification strategy\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli. Expression host selection can influence folding and PTM state, which may affect activity or binding in different assay formats.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePurification:\u003c\/strong\u003e Affinity-chromatography. Purification approach and formulation influence sample homogeneity and background signal in downstream biochemical measurements.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEndotoxin consideration:\u003c\/strong\u003e Reported endotoxin level is Please contact with the lab for this information.; this parameter can matter when recombinant proteins are used in cell-based systems sensitive to innate immune activation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details..\u003c\/p\u003e\u003ch2\u003eResearch interpretation\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eResearch interpretation:\u003c\/strong\u003e Recombinant protein reagents support controlled experiments such as interaction mapping, assay calibration, and reconstitution studies with defined inputs. Interpreting outcomes typically benefits from pairing the primary readout with orthogonal markers that report pathway state and complex formation.\u003c\/p\u003e","brand":"AtaGenix Laboratories","offers":[{"title":"100 ug","offer_id":53000849490285,"sku":"MF562012-100UG","price":411.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53000849523053,"sku":"MF562012-1MG","price":1727.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/abinScience_Protein_Placeholder_Image_50b7df68-fcbd-4a16-aa83-133f219eb8b8.jpg?v=1784821993"},{"product_id":"recombinant-human-ada-adenosine-deaminase-protein-n-his-sumo-bhp21403553","title":"Recombinant Human ADA\/Adenosine deaminase Protein, N-His-SUMO","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eTarget identity:\u003c\/strong\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is a protein. It is typically cell-type and isoform dependent (intracellular or extracellular).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is provided as a recombinant protein reagent for \u003cstrong\u003eresearch use only\u003c\/strong\u003e. Recombinant proteins are commonly used as defined molecular inputs in biochemical and cell-free systems, enabling controlled interrogation of binding, activity, and pathway-relevant interactions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eProtein identity context:\u003c\/strong\u003e ADA (expression region Thr57-Leu363; approx. molecular weight 46.97 kDa).\u003c\/p\u003e\u003ch2\u003eBiological significance and function\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is used in RUO research to interrogate molecular mechanisms, interaction networks, and pathway-linked phenotypes in experimental systems. This target is frequently explored in \u003cstrong\u003eMolecular \u0026amp; Cellular Biology\u003c\/strong\u003e research contexts.\u003c\/p\u003e\u003ch2\u003eMolecular characteristics\u003c\/h2\u003e\u003cp\u003eKey molecular attributes can influence binding behavior, stability, and assay background—especially for multimeric, disulfide-rich, or PTM-dependent targets.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e Thr57-Leu363\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 46.97 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003ePost-translational considerations:\u003c\/strong\u003e Prokaryotic expression typically yields a non-glycosylated recombinant form. This is often appropriate for many intracellular proteins and binding studies, while disulfide-rich or PTM-dependent extracellular targets may behave differently when native PTMs are required.\u003c\/p\u003e\u003ch2\u003eExpression and purification strategy\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli. Expression host selection can influence folding and PTM state, which may affect activity or binding in different assay formats.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePurification:\u003c\/strong\u003e Affinity-chromatography. Purification approach and formulation influence sample homogeneity and background signal in downstream biochemical measurements.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEndotoxin consideration:\u003c\/strong\u003e Reported endotoxin level is Please contact with the lab for this information.; this parameter can matter when recombinant proteins are used in cell-based systems sensitive to innate immune activation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details..\u003c\/p\u003e\u003ch2\u003eResearch interpretation\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eResearch interpretation:\u003c\/strong\u003e Recombinant protein reagents support controlled experiments such as interaction mapping, assay calibration, and reconstitution studies with defined inputs. Interpreting outcomes typically benefits from pairing the primary readout with orthogonal markers that report pathway state and complex formation.\u003c\/p\u003e","brand":"AtaGenix Laboratories","offers":[{"title":"100 ug","offer_id":53000951300461,"sku":"HF562022-100UG","price":411.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53000951333229,"sku":"HF562022-1MG","price":1727.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/abinScience_Protein_Placeholder_Image_9e68561a-1077-4925-af2b-6e888a69bc30.jpg?v=1784822089"},{"product_id":"recombinant-human-ada-protein-n-his-bhp21409503","title":"Recombinant Human ADA Protein, N-His","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eTarget identity:\u003c\/strong\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is a protein. It is typically cell-type and isoform dependent (intracellular or extracellular).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is provided as a recombinant protein reagent for \u003cstrong\u003eresearch use only\u003c\/strong\u003e. Recombinant proteins are commonly used as defined molecular inputs in biochemical and cell-free systems, enabling controlled interrogation of binding, activity, and pathway-relevant interactions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eProtein identity context:\u003c\/strong\u003e ADA (expression region Lys11-Val280; approx. molecular weight 32.47 kDa).\u003c\/p\u003e\u003ch2\u003eBiological significance and function\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is used in RUO research to interrogate molecular mechanisms, interaction networks, and pathway-linked phenotypes in experimental systems. This target is frequently explored in \u003cstrong\u003eMolecular \u0026amp; Cellular Biology\u003c\/strong\u003e research contexts.\u003c\/p\u003e\u003ch2\u003eMolecular characteristics\u003c\/h2\u003e\u003cp\u003eKey molecular attributes can influence binding behavior, stability, and assay background—especially for multimeric, disulfide-rich, or PTM-dependent targets.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e Lys11-Val280\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 32.47 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003ePost-translational considerations:\u003c\/strong\u003e Prokaryotic expression typically yields a non-glycosylated recombinant form. This is often appropriate for many intracellular proteins and binding studies, while disulfide-rich or PTM-dependent extracellular targets may behave differently when native PTMs are required.\u003c\/p\u003e\u003ch2\u003eExpression and purification strategy\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli. Expression host selection can influence folding and PTM state, which may affect activity or binding in different assay formats.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePurification:\u003c\/strong\u003e Affinity-chromatography. Purification approach and formulation influence sample homogeneity and background signal in downstream biochemical measurements.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEndotoxin consideration:\u003c\/strong\u003e Reported endotoxin level is Please contact with the lab for this information.; this parameter can matter when recombinant proteins are used in cell-based systems sensitive to innate immune activation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details..\u003c\/p\u003e\u003ch2\u003eResearch interpretation\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eResearch interpretation:\u003c\/strong\u003e Recombinant protein reagents support controlled experiments such as interaction mapping, assay calibration, and reconstitution studies with defined inputs. Interpreting outcomes typically benefits from pairing the primary readout with orthogonal markers that report pathway state and complex formation.\u003c\/p\u003e","brand":"AtaGenix Laboratories","offers":[{"title":"100 ug","offer_id":53001846096237,"sku":"HF562012-100UG","price":411.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53001846129005,"sku":"HF562012-1MG","price":1727.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/abinScience_Protein_Placeholder_Image_2665545d-ae7a-45a9-ac2a-1d150c0041b2.jpg?v=1784822492"},{"product_id":"recombinant-human-ada-bhp10800350","title":"Recombinant Human ADA","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is used in \u003cstrong\u003eresearch use only (RUO)\u003c\/strong\u003e settings as a defined recombinant protein reagent. Bench researchers commonly leverage recombinant proteins to create controlled experimental conditions for mechanistic studies, assay development, interaction mapping, and quantitative benchmarking across model systems.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eAlso known as:\u003c\/strong\u003e ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase.\u003c\/p\u003e\u003ch2\u003eBiological significance and function\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e is frequently used in RUO studies focused on \u003cstrong\u003emetabolic pathway regulation, energy homeostasis, and cellular bioenergetics\u003c\/strong\u003e. Recombinant protein reagents help researchers build defined systems for biochemical characterization, binding assays, and assay development where reproducibility and traceability matter.\u003c\/p\u003e\u003cp\u003eMechanistically, researchers often analyze how ADA participates in pathway networks through molecular interactions, localization, and regulated activity. Depending on the target class, this can involve receptor-mediated signaling, enzymatic catalysis, complex assembly, or structural organization that shapes downstream cellular phenotypes.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eResearch relevance:\u003c\/strong\u003e RUO studies frequently connect ADA to perturbations such as immune stimulation, stress signaling, differentiation cues, metabolic remodeling, or engineered genetic modulation—then interpret downstream readouts using complementary pathway markers.\u003c\/p\u003e\u003ch2\u003eMolecular characteristics\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eMolecular features matter in RUO experiments:\u003c\/strong\u003e domain boundaries, oligomerization state, and PTM sensitivity can influence binding behavior, stability, and functional readouts in vitro.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSource species:\u003c\/strong\u003e Human\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConstruct \/ expression region:\u003c\/strong\u003e aa 1-363\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApprox. molecular weight:\u003c\/strong\u003e 40.8 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Greater than 90% as determined by SDS-PAGE.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized from a 0.2 μm filtered solution of 10 mM Hepes, 150 mM NaCl with 5% trehalose, pH 7.4.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Centrifuge the vial before opening, reconstitute in sterile distilled water to a concentration of 0.1-1 mg\/ml by gently pipetting 2-3 times, don't vortex.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003ePTM considerations:\u003c\/strong\u003e Catalytic proteins can be sensitive to \u003cstrong\u003ecofactors\u003c\/strong\u003e, \u003cstrong\u003eredox state\u003c\/strong\u003e, and site-specific PTMs that tune activity or interactions in vivo. Whether those PTMs are present depends on expression host and construct design. Prokaryotic expression typically yields non-glycosylated protein; consider whether eukaryotic PTMs are required for your assay context.\u003c\/p\u003e\u003ch2\u003eExpression and purification strategy\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eExpression system:\u003c\/strong\u003e This protein is produced in a \u003cstrong\u003eprokaryotic (E. coli)\u003c\/strong\u003e system, which typically yields a defined, non-glycosylated form. This can be advantageous for mechanistic studies, binding assays, and antigen\/standard use where mammalian PTMs are not required.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePurification transparency (research credibility):\u003c\/strong\u003e In research-grade recombinant protein production, constructs are commonly purified via affinity and polishing steps (e.g., chromatography) to reduce contaminants and improve batch-to-batch consistency. When present, affinity tags (e.g., His\/GST\/Fc) can simplify purification; tag presence or removal can influence certain binding or structural assays.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eForm and handling context:\u003c\/strong\u003e Lyophilized proteins are frequently used in RUO labs to support stability during storage and shipment, while formulation components and reconstitution conditions can impact solubility and aggregation—important considerations when comparing studies across publications.\u003c\/p\u003e\u003ch2\u003eResearch interpretation\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eResearch interpretation:\u003c\/strong\u003e Catalytic readouts are often context-dependent, influenced by cofactors, partner proteins, and PTM state. recombinant \u003cstrong\u003eADA\u003c\/strong\u003e is commonly integrated with complementary pathway markers to interpret whether observed changes reflect altered activity, abundance, or complex formation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUsing recombinant protein as a defined reagent:\u003c\/strong\u003e recombinant ADA is commonly used as a quantitative input for assay calibration, antibody\/ligand binding studies, pathway reconstitution, and controlled perturbation experiments. Researchers often consider isoforms, fragments, or construct boundaries when comparing results across studies.\u003c\/p\u003e","brand":"Fine Test","offers":[{"title":"50 ug","offer_id":53013907374445,"sku":"P0627-50UG","price":455.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53013907407213,"sku":"P0627-200UG","price":910.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53013907439981,"sku":"P0627-1MG","price":2730.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/E8_9B_8B_E7_99_BD_5945b5fb-a697-4a1b-a956-d2f937b0be7d.jpg?v=1770539367"},{"product_id":"anti-mouse-ada-adenosine-deaminase-polyclonal-antibody-bha21417960","title":"Anti-Mouse ADA\/Adenosine deaminase Polyclonal Antibody","description":"\u003cp\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003cbr\u003e\nAnti-Mouse ADA\/Adenosine deaminase Polyclonal Antibody targets \u003cstrong\u003eADA\/Adenosine deaminase\u003c\/strong\u003e (Adenosine aminohydrolase). Frequently used across ELISA, IHC, WB workflows, depending on experimental design and sample type. This antibody is suited for workflows commonly used in Molecular \u0026amp; Cellular Biology research.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAlso known as:\u003c\/strong\u003e Adenosine aminohydrolase, Adenosine deaminase, 3.5.4.4, Ada.\u003c\/p\u003e\n\n\u003ch3\u003eTarget biology\u003c\/h3\u003e\n\u003cp\u003eADA\/Adenosine deaminase (Adenosine aminohydrolase) is annotated as adenosine aminohydrolase and is commonly profiled for expression and localization in relevant model systems. It is frequently investigated in contexts related to Molecular \u0026amp; Cellular Biology. Common alternative names and symbols used in the literature include: Adenosine deaminase, 3.5.4.4, Ada. Based on the annotated name\/class, the target is most often associated with context-dependent localization, though this can vary by model system.\u003c\/p\u003e\n\n\u003ch3\u003eHow this antibody helps\u003c\/h3\u003e\n\u003cp\u003eAs a polyclonal reagent, this antibody can provide strong sensitivity through recognition of multiple epitopes on the target. For best performance, interpret signal in the context of appropriate biological controls and orthogonal readouts when available.\u003c\/p\u003e\n\n\u003ch3\u003eAntigen \/ immunogen context\u003c\/h3\u003e\u003cp\u003eE. coli - derived recombinant Mouse ADA\/Adenosine deaminase (Met1-Gln352).\u003c\/p\u003e\n\n\u003ch3\u003eRecommended experimental notes\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eTitrate the antibody to optimize signal-to-noise for your specific sample type and detection system.\u003c\/li\u003e\n\u003cli\u003eUse appropriate positive and negative controls (e.g., target-high vs target-low samples, KO\/KD where available).\u003c\/li\u003e\n\u003cli\u003eFor Western blotting, use fresh protease (and phosphatase, if relevant) inhibitors and confirm the primary band at the expected molecular weight; additional bands may reflect isoforms or processing.\u003c\/li\u003e\n\u003cli\u003eFor IHC, optimize fixation and antigen retrieval (buffer\/pH\/heat) and include an isotype\/secondary-only control to assess background.\u003c\/li\u003e\n\u003cli\u003eFor ELISA, optimize capture\/detection pairing and run a standard curve in matrix-matched diluent when possible.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eAdditional notes\u003c\/h3\u003e\u003cp\u003eFor research use only.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic procedures.\u003c\/em\u003e\u003c\/p\u003e","brand":"AtaGenix Laboratories","offers":[{"title":"50 ug","offer_id":53037251854701,"sku":"MF562014-50UG","price":268.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53037893615981,"sku":"MF562014-100UG","price":378.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/MF562014-WB-1.jpg?v=1771750056"},{"product_id":"ada-antibody-bha17100276","title":"ADA Antibody","description":"\u003cp\u003eThis gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"NSJ Bioreagents","offers":[{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.08 ml","offer_id":53042864161133,"sku":"F40390-0.08ML","price":211.15,"currency_code":"USD","in_stock":true},{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.4 ml","offer_id":53042947064173,"sku":"F40390-0.4ML","price":452.17,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_4d836c39-8919-40eb-bac8-3ac92520b983.jpg?v=1771923625"},{"product_id":"ada-antibody-bha17100410","title":"ADA Antibody","description":"\u003cp\u003eAdenosine deaminase (ADA) catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion. [UniProt]\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Cytoplasm, cell membrane\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"NSJ Bioreagents","offers":[{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.08 ml","offer_id":53042867994989,"sku":"F41596-0.08ML","price":211.15,"currency_code":"USD","in_stock":true},{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.4 ml","offer_id":53042950439277,"sku":"F41596-0.4ML","price":452.17,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_225d30fa-9458-4596-a069-955b60df03a5.jpg?v=1771923657"},{"product_id":"zebrafish-ada-antibody-bha17102130","title":"Zebrafish Ada Antibody","description":"\u003cp\u003eCatalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. May act as a positive regulator of T-cell coactivation (By similarity).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"NSJ Bioreagents","offers":[{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.08 ml","offer_id":53042920718701,"sku":"F52652-0.08ML","price":211.15,"currency_code":"USD","in_stock":true},{"title":"In 1X PBS, pH 7.4, with 0.09% sodium azide \/ 0.4 ml","offer_id":53043003785581,"sku":"F52652-0.4ML","price":452.17,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_c5306ecd-c5ac-4812-b11b-8b345ba65f9e.jpg?v=1771923978"},{"product_id":"ada-antibody-adenosine-deaminase-bha17108942","title":"ADA Antibody \/ Adenosine deaminase","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eADA Antibody \/ Adenosine deaminase is a research-use antibody directed against \u003cstrong\u003eADA\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB, IHC-P, ELISA (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ADA.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e Adenosine Deaminase (also known as Adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Rabbit, Polyclonal (rabbit origin), Rabbit IgG.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified; Antigen affinity purified.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eReported\/predicted localization:\u003c\/strong\u003e Membrane, cytoplasm.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Mouse, Rat.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e A recombinant mouse partial protein corresponding to amino acids A2-H238 was used as the immunogen for the ADA antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eAdenosine Deaminase (also known as Adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress.\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for ADA, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine ADA abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e  \u003cli\u003eImmunohistochemistry for spatial mapping of target expression across tissues and cell types.\u003c\/li\u003e  \u003cli\u003eELISA-based detection or quantification in research assays (format- and epitope-dependent).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for ADA (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/P03958\n- NCBI Gene search for ADA (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=ADA\n- Ensembl gene search for ADA (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=ADA\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53044450165101,"sku":"RQ4048","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_229efdf7-a3cd-48e5-8fe7-7d0f41c5b0c7.jpg?v=1771938831"},{"product_id":"ada-antibody-bha17108943","title":"Ada Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eAda Antibody is a research-use antibody directed against \u003cstrong\u003eADA\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB, IHC-P, ELISA (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ADA.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e Adenosine Deaminase (also known as Adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Rabbit, Polyclonal (rabbit origin), Rabbit IgG.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified; Antigen affinity purified.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Mouse, Rat.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e A recombinant rat partial protein corresponding to amino acids A2-H241 was used as the immunogen for the Ada antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eAdenosine Deaminase (also known as Adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress.\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for ADA, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine ADA abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e  \u003cli\u003eImmunohistochemistry for spatial mapping of target expression across tissues and cell types.\u003c\/li\u003e  \u003cli\u003eELISA-based detection or quantification in research assays (format- and epitope-dependent).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for ADA (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/Q920P6\n- NCBI Gene search for ADA (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=ADA\n- Ensembl gene search for ADA (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=ADA\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53044450492781,"sku":"RQ4049","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_5cfe02d4-05aa-404f-909b-557ceb53322f.jpg?v=1771938831"},{"product_id":"ada-antibody-adenosine-deaminase-bha17109414","title":"ADA Antibody \/ Adenosine deaminase","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eADA Antibody \/ Adenosine deaminase is a research-use antibody directed against \u003cstrong\u003eADA\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB, IHC-P, FACS (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ADA.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e Adenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Mouse, clone 6D4, Mouse IgG2b.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified; Protein G affinity.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Human.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e Amino acids Q135-L363 from the human protein were used as the immunogen for the ADA antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eAdenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress.\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for ADA, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine ADA abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e  \u003cli\u003eImmunohistochemistry for spatial mapping of target expression across tissues and cell types.\u003c\/li\u003e  \u003cli\u003eFACS: commonly used to detect or compare ADA across experimental conditions (conceptual guidance only).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for ADA (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/P00813\n- NCBI Gene search for ADA (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=ADA\n- Ensembl gene search for ADA (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=ADA\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n- Human Protein Atlas search for ADA (HPA): https:\/\/www.proteinatlas.org\/search\/ADA\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53044474970477,"sku":"RQ4623","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_6ab83c27-c7ec-447d-be96-442eb8b6c620.jpg?v=1771938941"},{"product_id":"recombinant-mouse-adenosine-deaminase-ada-bhp10514085","title":"Recombinant Mouse Adenosine deaminase (Ada)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Mouse Adenosine deaminase (Ada) is a recombinant protein preparation derived from Mus musculus (Mouse). It is commonly used as a defined reagent for assay development, binding studies, and analytical controls where consistent protein specifications are required.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 2-352aa.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli (may influence folding and post-translational modifications).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTag\/format:\u003c\/strong\u003e C-terminal 6xHis-tagged; Liquid or Lyophilized powder.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpected size:\u003c\/strong\u003e 46.8 kDa (as provided).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Greater than 95% as determined by SDS-PAGE.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eRegion choice, expression system, and tag\/format can influence folding, post-translational modifications, and interaction behavior in downstream assays.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eCatalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion. Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion. Enhances CD4+ T-cell differentiation and proliferation. Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change. Stimulates plasminogen activation. Plays a role in male fertility. Plays a protective role in early postimplantation embryonic development.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eDomain- and isoform-aware assay design to improve biological interpretation across model systems.\u003c\/li\u003e\n\u003cli\u003eQuantitative workflows emphasizing calibration standards, spike-in controls, and cross-lot comparability.\u003c\/li\u003e\n\u003cli\u003eIn vitro binding\/kinetics profiling (SPR\/BLI) to connect biochemical interactions with cellular phenotypes.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003ePrepare aliquots of Ada for reproducible in vitro assays (minimize freeze–thaw).\u003c\/li\u003e\n\u003cli\u003eUse Ada as a calibration standard in quantitative assays (standard curve setup).\u003c\/li\u003e\n\u003cli\u003eMeasure binding interactions to Ada by SPR\/BLI (kinetic profiling in vitro).\u003c\/li\u003e\n\u003cli\u003eGenerate antibodies to Ada and benchmark specificity in ELISA\/WB (control samples).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpret results in the context of the biological system, assay format, and any known domain\/isoform constraints for the target.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConsider species- and isoform-specific differences when comparing results across models or homologs.\u003c\/li\u003e\n\u003cli\u003eFor quantitative assays, include appropriate negative controls and matrix-matched spike-in concepts to assess non-specific signal.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProtKB entry (P03958) — UniProt: https:\/\/www.uniprot.org\/uniprotkb\/P03958 - NCBI Gene search (Ada) — NCBI: https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Ada - PubMed search — NLM: https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ada - Reactome pathway browser — Reactome: https:\/\/reactome.org\/ - InterPro protein family resource — EMBL-EBI: https:\/\/www.ebi.ac.uk\/interpro\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53059248226669,"sku":"CSB-EP001268MO-1MG","price":1866.36,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53059338895725,"sku":"CSB-EP001268MO-100UG","price":431.57,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53059338928493,"sku":"CSB-EP001268MO-20UG","price":230.72,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP001268MO-SDS.jpg?v=1772280085"},{"product_id":"anti-ada-antibody-picoband-bha21000827","title":"Anti-ADA Antibody Picoband®","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis antibody is intended for detection of \u003cstrong\u003eADA (Adenosine deaminase)\u003c\/strong\u003e in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality\/clone information, and detection modality.\u003c\/p\u003e \u003cp\u003e\u003cem\u003eVendor notes:\u003c\/em\u003e Boster Bio Anti-ADA Antibody Picoband® catalog # PB9914. Tested in Flow Cytometry, IHC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Rabbit Polyclonal Rabbit IgG\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eImmunogen \/ epitope context:\u003c\/strong\u003e E. coli-derived human ADA recombinant protein (Position: Q135-L363). Human ADA shares 82.5% and 82.9% amino acid (aa) sequence identity with mouse and rat ADA, respectively. (reported region: Q135-L363).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight context:\u003c\/strong\u003e reported MW: 41 kDa; calculated MW: 40764 MW\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eReactivity:\u003c\/strong\u003e Human,Mouse,Rat\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e Flow Cytometry, IHC, WB\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eAs a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eAdenosine deaminase; Adenosine deaminase. Adenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress. Functional note: Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes inly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte- epithelial cell adhesion. . Reported localization: Cell membrane; Peripheral membrane protein; Extracellular side. Cell junction. Cytoplasmic vesicle lumen . Cytoplasm . Colocalized with DPP4 at the cell junction in lymphocyte-epithelial cell adhesion. Expression\/tissue context: Found in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eCancer: Researchers commonly examine how ADA (Adenosine deaminase) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eCancer Metabolism: Researchers commonly examine how ADA (Adenosine deaminase) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eChromatin Modifying Enzymes: Researchers commonly examine how ADA (Adenosine deaminase) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: compare relative ADA (Adenosine deaminase) levels across conditions; band patterns may reflect isoforms and processing.\u003c\/li\u003e\n\u003cli\u003eIHC\/IHC-F: assess spatial distribution of ADA (Adenosine deaminase) across tissue regions and cell types using matched controls.\u003c\/li\u003e\n\u003cli\u003eFlow cytometry: quantify target-positive populations and shifts in expression; gating strategy and background staining controls are essential.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eSpecificity notes:\u003c\/strong\u003e No cross reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e No cross-reactivity with other proteins\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD\/KO samples when available.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProt entry for P00813: https:\/\/www.uniprot.org\/uniprotkb\/P00813\/entry - PubMed search (ADA): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=ADA - NCBI Gene search (ADA): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=ADA - Antibody validation concepts (NIH): https:\/\/www.nih.gov\/research-training\/rigor-reproducibility --\u003e","brand":"Boster Bio","offers":[{"title":"100 ug\/vial \/ Unconjugated","offer_id":53066838835565,"sku":"PB9914","price":381.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Biotin","offer_id":53067185684845,"sku":"PB9914-Biotin","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Cy3","offer_id":53067185717613,"sku":"PB9914-Cy3","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro488","offer_id":53067185750381,"sku":"PB9914-Fluoro488","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro550","offer_id":53067185783149,"sku":"PB9914-Fluoro550","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro594","offer_id":53067185815917,"sku":"PB9914-Fluoro594","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ FITC","offer_id":53067185848685,"sku":"PB9914-FITC","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ HRP","offer_id":53067185881453,"sku":"PB9914-HRP","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ APC","offer_id":53067185914221,"sku":"PB9914-APC","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ PE","offer_id":53067185946989,"sku":"PB9914-PE","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro647","offer_id":53067185979757,"sku":"PB9914-Fluoro647","price":690.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Carrier Free","offer_id":53067186012525,"sku":"PB9914-carrier-free","price":381.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pb9914-ada-primary-antibodies-wb-testing-1.jpg?v=1772608219"},{"product_id":"anti-ada-antibody-picoband-bha21001398","title":"Anti-ADA Antibody Picoband®","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis antibody is intended for detection of \u003cstrong\u003eAda (SPARC)\u003c\/strong\u003e in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality\/clone information, and detection modality.\u003c\/p\u003e \u003cp\u003e\u003cem\u003eVendor notes:\u003c\/em\u003e Boster Bio Anti-ADA Antibody Picoband® catalog # A00866-1. Tested in ELISA, IHC, WB applications. This antibody reacts with Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Rabbit Polyclonal Rabbit IgG\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eImmunogen \/ epitope context:\u003c\/strong\u003e E. coli-derived mouse ADA recombinant protein (Position: A2-H238). (reported region: A2-H238).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight context:\u003c\/strong\u003e reported MW: 45 kDa; calculated MW: 34632 MW\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eReactivity:\u003c\/strong\u003e Mouse,Rat\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e ELISA, IHC, WB\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eAs a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eSPARC; adenosine deaminase. Adenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress. Functional note: Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine (PubMed:9272950). Plays an important role in purine metabolism and in adenosine homeostasis (PubMed:9272950, PubMed:10720488). Modulates signaling by extracellular adenosine, and so contributes inly to cellular signaling events (PubMed:11435465). Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (By similarity). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (By similarity). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (By similarity). Stimulates plasminogen activation (By similarity). Plays a role in male fertility (By similarity). Plays a protective role in early postimplantation embryonic development (PubMed:9272950). Reported localization: Cell membrane; Peripheral membrane protein; Extracellular side. Cell junction. Expression\/tissue context: Detected in brain neurons in the median emninence (at protein level) (PubMed:8783262). Expressed in secondary deciduum (at protein level) (PubMed:9272950). Found in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eCancer: Researchers commonly examine how Ada (SPARC) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eCancer Metabolism: Researchers commonly examine how Ada (SPARC) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eChromatin Modifying Enzymes: Researchers commonly examine how Ada (SPARC) relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: compare relative Ada (SPARC) levels across conditions; band patterns may reflect isoforms and processing.\u003c\/li\u003e\n\u003cli\u003eIHC\/IHC-F: assess spatial distribution of Ada (SPARC) across tissue regions and cell types using matched controls.\u003c\/li\u003e\n\u003cli\u003eELISA-compatible use: when applicable, interpret signal as relative abundance across sample sets with consistent handling and dilution strategy.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eSpecificity notes:\u003c\/strong\u003e No cross reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e No cross-reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD\/KO samples when available.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProt entry for P03958: https:\/\/www.uniprot.org\/uniprotkb\/P03958\/entry - PubMed search (Ada): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ada - NCBI Gene search (Ada): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Ada - Antibody validation concepts (NIH): https:\/\/www.nih.gov\/research-training\/rigor-reproducibility --\u003e","brand":"Boster Bio","offers":[{"title":"100 ug\/vial \/ Unconjugated","offer_id":53066859512173,"sku":"A00866-1","price":381.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Biotin","offer_id":53067396186477,"sku":"A00866-1-Biotin","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Cy3","offer_id":53067396219245,"sku":"A00866-1-Cy3","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro488","offer_id":53067396252013,"sku":"A00866-1-Fluoro488","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro550","offer_id":53067396284781,"sku":"A00866-1-Fluoro550","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro594","offer_id":53067396317549,"sku":"A00866-1-Fluoro594","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ FITC","offer_id":53067396350317,"sku":"A00866-1-FITC","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ HRP","offer_id":53067396383085,"sku":"A00866-1-HRP","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ APC","offer_id":53067396415853,"sku":"A00866-1-APC","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ PE","offer_id":53067396448621,"sku":"A00866-1-PE","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro647","offer_id":53067396481389,"sku":"A00866-1-Fluoro647","price":690.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Carrier Free","offer_id":53067396514157,"sku":"A00866-1-carrier-free","price":381.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/a00866-1-ada-primary-antibodies-wb-testing-1_1.jpg?v=1772608320"},{"product_id":"anti-ada-antibody-picoband-bha21001399","title":"Anti-ADA Antibody Picoband®","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis antibody is intended for detection of \u003cstrong\u003eAda\u003c\/strong\u003e in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality\/clone information, and detection modality.\u003c\/p\u003e \u003cp\u003e\u003cem\u003eVendor notes:\u003c\/em\u003e Boster Bio Anti-ADA Antibody Picoband® catalog # A00866-2. Tested in ELISA, IHC, WB applications. This antibody reacts with Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Rabbit Polyclonal Rabbit IgG\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eImmunogen \/ epitope context:\u003c\/strong\u003e E. coli-derived rat ADA recombinant protein (Position: A2-H241). (reported region: A2-H241).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight context:\u003c\/strong\u003e reported MW: 41 kDa; calculated MW: nan\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eReactivity:\u003c\/strong\u003e Mouse,Rat\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e ELISA, IHC, WB\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eAs a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eadenosine deaminase. Adenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress. Functional note: Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes inly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte- epithelial cell adhesion. Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion. Enhances CD4+ T-cell differentiation and proliferation. Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change. Stimulates plasminogen activation. Plays a role in male fertility. Plays a protective role in early postimplantation embryonic development. Reported localization: Cell membrane; Peripheral membrane protein; Extracellular side. Cell junction. Expression\/tissue context: Detected in brain and liver (at protein level).\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eCancer: Researchers commonly examine how Ada relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eCancer Metabolism: Researchers commonly examine how Ada relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eChromatin Modifying Enzymes: Researchers commonly examine how Ada relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: compare relative Ada levels across conditions; band patterns may reflect isoforms and processing.\u003c\/li\u003e\n\u003cli\u003eIHC\/IHC-F: assess spatial distribution of Ada across tissue regions and cell types using matched controls.\u003c\/li\u003e\n\u003cli\u003eELISA-compatible use: when applicable, interpret signal as relative abundance across sample sets with consistent handling and dilution strategy.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eSpecificity notes:\u003c\/strong\u003e No cross reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e No cross-reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD\/KO samples when available.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProt entry for Q920P6: https:\/\/www.uniprot.org\/uniprotkb\/Q920P6\/entry - PubMed search (Ada): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ada - NCBI Gene search (Ada): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Ada - Antibody validation concepts (NIH): https:\/\/www.nih.gov\/research-training\/rigor-reproducibility --\u003e","brand":"Boster Bio","offers":[{"title":"100 ug\/vial \/ Unconjugated","offer_id":53066859643245,"sku":"A00866-2","price":381.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Biotin","offer_id":53067394744685,"sku":"A00866-2-Biotin","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Cy3","offer_id":53067394777453,"sku":"A00866-2-Cy3","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro488","offer_id":53067394810221,"sku":"A00866-2-Fluoro488","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro550","offer_id":53067394842989,"sku":"A00866-2-Fluoro550","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro594","offer_id":53067394875757,"sku":"A00866-2-Fluoro594","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ FITC","offer_id":53067394908525,"sku":"A00866-2-FITC","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ HRP","offer_id":53067394941293,"sku":"A00866-2-HRP","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ APC","offer_id":53067394974061,"sku":"A00866-2-APC","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ PE","offer_id":53067395006829,"sku":"A00866-2-PE","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro647","offer_id":53067395039597,"sku":"A00866-2-Fluoro647","price":690.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Carrier Free","offer_id":53067395072365,"sku":"A00866-2-carrier-free","price":381.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/a00866-2-ada-primary-antibodies-wb-testing-1_1.jpg?v=1772608328"},{"product_id":"anti-ada-antibody-picoband-monoclonal-6d4-bha21001964","title":"Anti-ADA Antibody Picoband® (monoclonal, 6D4)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis antibody is intended for detection of \u003cstrong\u003eADA\u003c\/strong\u003e in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality\/clone information, and detection modality.\u003c\/p\u003e \u003cp\u003e\u003cem\u003eVendor notes:\u003c\/em\u003e Boster Bio Anti-ADA Antibody Picoband® (monoclonal, 6D4) catalog # M00866. Tested in Flow Cytometry, IHC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Mouse Monoclonal Mouse IgG2b\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eClone number:\u003c\/strong\u003e Clone: 6D4\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eImmunogen \/ epitope context:\u003c\/strong\u003e E. coli-derived human ADA recombinant protein (Position: Q135-L363). Human ADA shares 82.5% and 82.9% amino acid (aa) sequence identity with mouse and rat ADA, respectively. (reported region: Q135-L363).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight context:\u003c\/strong\u003e reported MW: 45 kDa; calculated MW: nan\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eReactivity:\u003c\/strong\u003e Human\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e Flow Cytometry, IHC, WB\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eAs a monoclonal antibody, the reagent targets a defined epitope, supporting consistency across experiments; epitope masking by PTMs or conformational changes can affect signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eadenosine deaminase. Adenosine Deaminase (also known as adenosine aminohydrolase, or ADA) is an enzyme involved in purine metabolism. Primarily, ADA in humans is involved in the development and maintenance of the immune system. However, ADA association has also been observed with epithelial cell differentiation, neurotransmission, and gestation maintenance. It has also been proposed that ADA, in addition to adenosine breakdown, stimulates release of excitatory amino acids and is necessary to the coupling of A1 adenosine receptors and heterotrimeric G proteins. Adenosine deaminase deficiency leads to pulmonary fibrosis, suggesting that chronic exposure to high levels of adenosine can exacerbate inflammation responses rather than suppressing them. It has also been recognized that adenosine deaminase protein and activity is upregulated in mouse hearts that overexpress HIF-1 alpha, which in part explains the attenuated levels of adenosine in HIF-1 alpha expressing hearts during ischemic stress. Functional note: Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine (PubMed:8452534, PubMed:16670267). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes inly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte- epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Reported localization: Cell membrane Expression\/tissue context: Found in all tissues, occurs in large amounts in T-lymphocytes (PubMed:20959412). Expressed at the time of weaning in gastrointestinal tissues.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eCancer: Researchers commonly examine how ADA relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eCancer Metabolism: Researchers commonly examine how ADA relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e\n\u003cli\u003eChromatin Modifying Enzymes: Researchers commonly examine how ADA relates to this theme using model systems and orthogonal readouts.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: compare relative ADA levels across conditions; band patterns may reflect isoforms and processing.\u003c\/li\u003e\n\u003cli\u003eIHC\/IHC-F: assess spatial distribution of ADA across tissue regions and cell types using matched controls.\u003c\/li\u003e\n\u003cli\u003eFlow cytometry: quantify target-positive populations and shifts in expression; gating strategy and background staining controls are essential.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eSpecificity notes:\u003c\/strong\u003e No cross reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e No cross-reactivity with other proteins.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControls:\u003c\/strong\u003e Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD\/KO samples when available.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProt entry for P00813: https:\/\/www.uniprot.org\/uniprotkb\/P00813\/entry - PubMed search (ADA): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=ADA - NCBI Gene search (ADA): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=ADA - Antibody validation concepts (NIH): https:\/\/www.nih.gov\/research-training\/rigor-reproducibility --\u003e","brand":"Boster Bio","offers":[{"title":"100 ug\/vial \/ Unconjugated","offer_id":53066876485997,"sku":"M00866","price":381.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Biotin","offer_id":53067578114413,"sku":"M00866-Biotin","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Cy3","offer_id":53067578147181,"sku":"M00866-Cy3","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro488","offer_id":53067578179949,"sku":"M00866-Fluoro488","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro550","offer_id":53067578212717,"sku":"M00866-Fluoro550","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro594","offer_id":53067578245485,"sku":"M00866-Fluoro594","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ FITC","offer_id":53067578278253,"sku":"M00866-FITC","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ HRP","offer_id":53067578311021,"sku":"M00866-HRP","price":587.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ APC","offer_id":53067578343789,"sku":"M00866-APC","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ PE","offer_id":53067578376557,"sku":"M00866-PE","price":844.6,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Fluoro647","offer_id":53067578409325,"sku":"M00866-Fluoro647","price":690.1,"currency_code":"USD","in_stock":true},{"title":"100 ug\/vial \/ Carrier Free","offer_id":53067578442093,"sku":"M00866-carrier-free","price":381.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m00866-ada-primary-antibodies-wb-testing-1_1.jpg?v=1772608411"},{"product_id":"anti-ada-rabbit-monoclonal-antibody-bha21009883","title":"Anti-ADA Rabbit Monoclonal Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis product is an anti-ADA antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 23A88; isotype IgG; reactivity: Human,Rat. Reported application contexts include WB, ICC, IF, IP (as provided in the source record). Boster Bio Anti-ADA Rabbit Monoclonal Antibody catalog # M00866-1. Tested in WB, ICC\/IF, IP applications. This antibody reacts with Human, Rat.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ADA (Aquaporin-1).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone 23A88; isotype IgG.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost:\u003c\/strong\u003e Rabbit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human,Rat (confirm in your model system with appropriate controls).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eADA (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Forms a water-specific channel that provides the plasma membranes of red cells and kidney proximal tubules with high permeability to water, thereby permitting water to move in the ion of an osmotic gradient. . Reported cellular localization context: Cell membrane ; Multi-pass membrane protein . Tissue expression notes (as provided): Detected in erythrocytes (at protein level). Expressed in a number of tissues including erythrocytes, renal tubules, retinal pigment epithelium, heart, lung, skeletal muscle, kidney and pancreas. Weakly expressed in brain, placenta and liver. .\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eResearch context keywords from the source record include: Channels,Metabolism,Plasma Membrane,Signal Transduction,Vitamins\/Minerals.\u003c\/li\u003e\n\u003cli\u003eCurrent studies often focus on connecting target abundance\/localization to pathway perturbations across models, tissues, and cell states.\u003c\/li\u003e\n\u003cli\u003eQuantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eWestern blotting (WB):\u003c\/strong\u003e assess relative target abundance across samples, treatments, or time-points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence\/ICC (IF\/ICC):\u003c\/strong\u003e visualize subcellular localization patterns and cell-to-cell heterogeneity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunoprecipitation (IP):\u003c\/strong\u003e enrich target complexes for downstream immunoblot or interaction analyses.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWorkflow ideas (metafield): Validate ADA antibody specificity using KO\/KD control samples (WB\/IF\/IHC as appropriate), Detect ADA expression by Western blot in cell or tissue lysates, Localize ADA by immunofluorescence\/immunocytochemistry in cultured cells, Enrich ADA by immunoprecipitation from lysates for downstream analysis\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eConsider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.\u003c\/li\u003e\n\u003cli\u003eApparent molecular weight may vary by sample type and processing (observed MW: 45 kDa; calculated MW: 28526 MW).\u003c\/li\u003e\n\u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype, KO\/KD samples) and orthogonal validation when feasible.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eAdditional product details (from the source record)\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight (observed):\u003c\/strong\u003e 45 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCellular localization (provided):\u003c\/strong\u003e Cell membrane ; Multi-pass membrane protein .\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTissue details (provided):\u003c\/strong\u003e Detected in erythrocytes (at protein level). Expressed in a number of tissues including erythrocytes, renal tubules, retinal pigment epithelium, heart, lung, skeletal muscle, kidney and pancreas. Weakly expressed in brain, placenta and liver. .\u003c\/li\u003e\n\u003c\/ul\u003e \u003c!-- Sources (internal): - Antibodies — a laboratory manual overview — Cold Spring Harbor Protocols — https:\/\/cshprotocols.cshlp.org\/ - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Antibody validation and reproducibility — Nature methods (collections) — https:\/\/www.nature.com\/collections\/ - Immunohistochemistry\/Immunofluorescence basics — NIH \/ NCBI Bookshelf — https:\/\/www.ncbi.nlm.nih.gov\/books\/ --\u003e","brand":"Boster Bio","offers":[{"title":"100 uL\/vial \/ Unconjugated","offer_id":53071986819437,"sku":"M00866-1","price":381.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m00866-1-wb7.jpg?v=1772619123"},{"product_id":"ada-crispr-knockout-293t-cell-line-bhc10902508","title":"ADA CRISPR Knockout 293T Cell Line","description":"","brand":"Applied Biological Materials (abm) Inc.","offers":[{"title":"1x10\u003csup\u003e6\u003c\/sup\u003e cells \/ 1.0 ml","offer_id":53180718678381,"sku":"T3000241","price":1802.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/3T1yD3XaUUDxjPh9io4M7ib2PPAvxcTv99QrSfMg.png?v=1774960859"},{"product_id":"ada-antibody-bha10500140","title":"ADA Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, with confirmed utility in ELISA, WB, IHC, IF. Designed to detect ADA in Human, supporting researchers in epigenetics and nuclear signaling contexts.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Recombinant Human Adenosine deaminase protein (157-343AA) — determines the epitope region recognized; confirm epitope compatibility with your sample preparation and expected PTMs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Mismatched secondaries result in no signal. Consider host species when multiplexing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal:\u003c\/strong\u003e Recognizes multiple epitopes — robust signal across varied preparations, with inherent lot-to-lot variability. Isotype controls and lot qualification recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Secondary antibodies and isotype controls must match IgG from Rabbit. Relevant for multiplexing and Protein A\/G compatibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Protein G purification):\u003c\/strong\u003e Reduces non-specific immunoglobulin populations, improving signal-to-noise in quantitative immunoassay formats.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also known as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection outcomes. Researchers are encouraged to consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology relevant to epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eELISA:\u003c\/strong\u003e Sandwich or indirect ELISA quantifies soluble\/secreted target in biological fluids or cell culture supernatants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e Western blot confirms target MW and detects isoforms\/fragments under denaturing conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC:\u003c\/strong\u003e IHC visualizes target expression in FFPE or frozen sections; optimize antigen retrieval and secondary detection per tissue type.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIF:\u003c\/strong\u003e IF localizes target at subcellular resolution in fixed cells\/sections; fixation and permeabilization conditions affect epitope accessibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Include IgG from Rabbit at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity\/isoforms:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms — validate with siRNA KD, KO lysate, or recombinant protein controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) may influence performance; pilot dilution linearity and spike-recovery experiments before full quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human; extrapolation to untested species requires empirical validation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 ug","offer_id":53238390948205,"sku":"CSB-PA001268EA01HU-50UG","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53238494953837,"sku":"CSB-PA001268EA01HU-100UG","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA001268EA01HU-WB.jpg?v=1776670170"},{"product_id":"ada-antibody-biotin-conjugated-bha10500143","title":"ADA Antibody, Biotin conjugated","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, conjugated with Biotin, with confirmed utility in ELISA. Designed to detect ADA in Human, supporting researchers in epigenetics and nuclear signaling contexts.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Recombinant Human Adenosine deaminase protein (157-343AA) — determines the epitope region recognized; confirm epitope compatibility with your sample preparation and expected PTMs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Mismatched secondaries result in no signal. Consider host species when multiplexing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal:\u003c\/strong\u003e Recognizes multiple epitopes — robust signal across varied preparations, with inherent lot-to-lot variability. Isotype controls and lot qualification recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Secondary antibodies and isotype controls must match IgG from Rabbit. Relevant for multiplexing and Protein A\/G compatibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Protein G purification):\u003c\/strong\u003e Reduces non-specific immunoglobulin populations, improving signal-to-noise in quantitative immunoassay formats.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiotin conjugate:\u003c\/strong\u003e Signal amplification via streptavidin\/avidin-coupled reporters. Block endogenous biotin in liver, kidney, or biotin-supplemented samples.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also known as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection outcomes. Researchers are encouraged to consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology relevant to epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eELISA:\u003c\/strong\u003e Sandwich or indirect ELISA quantifies soluble\/secreted target in biological fluids or cell culture supernatants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Include IgG from Rabbit at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity\/isoforms:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms — validate with siRNA KD, KO lysate, or recombinant protein controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) may influence performance; pilot dilution linearity and spike-recovery experiments before full quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human; extrapolation to untested species requires empirical validation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 ug","offer_id":53238391374189,"sku":"CSB-PA001268ED01HU-50UG","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53238495936877,"sku":"CSB-PA001268ED01HU-100UG","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA001268EA01HU-WB_8840f402-7c24-411e-8c0d-7b0af8e47be4.jpg?v=1782237418"},{"product_id":"ada-antibody-fitc-conjugated-bha10500142","title":"ADA Antibody, FITC conjugated","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, conjugated with FITC. Designed to detect ADA in Human, supporting researchers in epigenetics and nuclear signaling contexts.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Recombinant Human Adenosine deaminase protein (157-343AA) — determines the epitope region recognized; confirm epitope compatibility with your sample preparation and expected PTMs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Mismatched secondaries result in no signal. Consider host species when multiplexing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal:\u003c\/strong\u003e Recognizes multiple epitopes — robust signal across varied preparations, with inherent lot-to-lot variability. Isotype controls and lot qualification recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Secondary antibodies and isotype controls must match IgG from Rabbit. Relevant for multiplexing and Protein A\/G compatibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Protein G purification):\u003c\/strong\u003e Reduces non-specific immunoglobulin populations, improving signal-to-noise in quantitative immunoassay formats.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFITC conjugate:\u003c\/strong\u003e Direct fluorescence (Ex ~490 nm \/ Em ~525 nm). Susceptible to photobleaching — use antifade reagents; protect from light.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also known as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection outcomes. Researchers are encouraged to consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology relevant to epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eRefer to the product datasheet for confirmed application data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Include IgG from Rabbit at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity\/isoforms:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms — validate with siRNA KD, KO lysate, or recombinant protein controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) may influence performance; pilot dilution linearity and spike-recovery experiments before full quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human; extrapolation to untested species requires empirical validation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 ug","offer_id":53238391636333,"sku":"CSB-PA001268EC01HU-50UG","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53238495314285,"sku":"CSB-PA001268EC01HU-100UG","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA001268EA01HU-WB_a6a25563-bc65-499a-a83a-a4a535a10646.jpg?v=1782237418"},{"product_id":"ada-antibody-hrp-conjugated-bha10500141","title":"ADA Antibody, HRP conjugated","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, conjugated with HRP, with confirmed utility in ELISA. Designed to detect ADA in Human, supporting researchers in epigenetics and nuclear signaling contexts.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Recombinant Human Adenosine deaminase protein (157-343AA) — determines the epitope region recognized; confirm epitope compatibility with your sample preparation and expected PTMs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Mismatched secondaries result in no signal. Consider host species when multiplexing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal:\u003c\/strong\u003e Recognizes multiple epitopes — robust signal across varied preparations, with inherent lot-to-lot variability. Isotype controls and lot qualification recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Secondary antibodies and isotype controls must match IgG from Rabbit. Relevant for multiplexing and Protein A\/G compatibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Protein G purification):\u003c\/strong\u003e Reduces non-specific immunoglobulin populations, improving signal-to-noise in quantitative immunoassay formats.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHRP conjugate:\u003c\/strong\u003e Direct chromogenic (TMB\/OPD) or chemiluminescent (ECL) detection. Quench endogenous peroxidase in tissue applications. No secondary required.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also known as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection outcomes. Researchers are encouraged to consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology relevant to epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eELISA:\u003c\/strong\u003e Sandwich or indirect ELISA quantifies soluble\/secreted target in biological fluids or cell culture supernatants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Include IgG from Rabbit at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity\/isoforms:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms — validate with siRNA KD, KO lysate, or recombinant protein controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) may influence performance; pilot dilution linearity and spike-recovery experiments before full quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human; extrapolation to untested species requires empirical validation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 ug","offer_id":53238392029549,"sku":"CSB-PA001268EB01HU-50UG","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53238496788845,"sku":"CSB-PA001268EB01HU-100UG","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA001268EA01HU-WB_989b0d5b-6dad-4609-806e-282e908e01cf.jpg?v=1782237418"},{"product_id":"ada-antibody-bha10551356","title":"ADA Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, with confirmed utility in ELISA, WB, IHC. It is designed to detect ADA protein in Human, Mouse, Rat and supports researchers working in epigenetics and nuclear signaling contexts where consistent antibody performance is required.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Fusion protein of Human ADA — the immunizing antigen determines the epitope region; confirm epitope compatibility with sample preparation and expected post-translational modifications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost species (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Use matched secondaries to avoid no-signal or cross-reactivity issues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal format:\u003c\/strong\u003e Recognizes multiple epitopes, providing robust signal across varied preparations and species variants. Inherent lot-to-lot variability requires appropriate controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Compatible with standard Protein A\/G purification and widely supported by secondary reagents. Include an isotype-matched control at equivalent concentration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Antigen affinity purification):\u003c\/strong\u003e Enriches for specific immunoglobulin classes, reducing non-specific populations and improving signal-to-noise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also referred to as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein target studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection and experimental design. Consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology, including known isoforms, interactors, and disease-relevant expression patterns in epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eELISA:\u003c\/strong\u003e Sandwich or indirect ELISA can quantify soluble target in biological fluids or culture supernatants. Ensure samples fall within the linear detection range.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e Western blot confirms target molecular weight and distinguishes isoforms under denaturing conditions. Expected band size should align with reported MW.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC:\u003c\/strong\u003e IHC visualizes target in FFPE or frozen tissue sections. Optimize antigen retrieval method and secondary detection for each tissue type.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms. Orthogonal validation (siRNA, KO lysate, recombinant protein) is recommended to confirm signal specificity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) can affect performance. Pilot dilution linearity and spike-recovery experiments are recommended for quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human, Mouse, Rat. Extrapolation to untested species requires empirical validation given potential epitope sequence divergence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio datasheet: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 uL","offer_id":53247021154669,"sku":"CSB-PA776767-50UL","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 uL","offer_id":53247123423597,"sku":"CSB-PA776767-100UL","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA776767-P.jpg?v=1776776266"},{"product_id":"ada-antibody-bha10551355","title":"ADA Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis is a polyclonal anti-ADA antibody raised in Rabbit, with confirmed utility in ELISA, WB, IHC. It is designed to detect ADA protein in Human, Mouse, Rat and supports researchers working in epigenetics and nuclear signaling contexts where consistent antibody performance is required.\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Fusion protein of Human ADA — the immunizing antigen determines the epitope region; confirm epitope compatibility with sample preparation and expected post-translational modifications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost species (Rabbit):\u003c\/strong\u003e Requires anti-rabbit-IgG secondary reagents. Use matched secondaries to avoid no-signal or cross-reactivity issues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolyclonal format:\u003c\/strong\u003e Recognizes multiple epitopes, providing robust signal across varied preparations and species variants. Inherent lot-to-lot variability requires appropriate controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype (IgG):\u003c\/strong\u003e Compatible with standard Protein A\/G purification and widely supported by secondary reagents. Include an isotype-matched control at equivalent concentration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurification (Antigen affinity purification):\u003c\/strong\u003e Enriches for specific immunoglobulin classes, reducing non-specific populations and improving signal-to-noise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eADA\u003c\/strong\u003e (also referred to as ada, ADA_HUMAN, ADA1, Adenosine aminohydrolase, Adenosine deaminase) is a protein target studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection and experimental design. Consult UniProt, NCBI Gene, and primary literature for current annotation of ADA biology, including known isoforms, interactors, and disease-relevant expression patterns in epigenetics and nuclear signaling.\u003c\/p\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eELISA:\u003c\/strong\u003e Sandwich or indirect ELISA can quantify soluble target in biological fluids or culture supernatants. Ensure samples fall within the linear detection range.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e Western blot confirms target molecular weight and distinguishes isoforms under denaturing conditions. Expected band size should align with reported MW.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC:\u003c\/strong\u003e IHC visualizes target in FFPE or frozen tissue sections. Optimize antigen retrieval method and secondary detection for each tissue type.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsotype controls:\u003c\/strong\u003e Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross-reactivity:\u003c\/strong\u003e Polyclonal preparations may cross-react with related proteins or isoforms. Orthogonal validation (siRNA, KO lysate, recombinant protein) is recommended to confirm signal specificity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Sample matrix (serum, plasma, lysate, homogenate) can affect performance. Pilot dilution linearity and spike-recovery experiments are recommended for quantitative studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Confirmed for Human, Mouse, Rat. Extrapolation to untested species requires empirical validation given potential epitope sequence divergence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is a polyclonal antibody purified from rabbit antiserum.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProt: https:\/\/www.uniprot.org\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n- Cusabio datasheet: https:\/\/www.cusabio.com\n- Human Protein Atlas: https:\/\/www.proteinatlas.org\n- PubMed: https:\/\/pubmed.ncbi.nlm.nih.gov\n--\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"50 uL","offer_id":53247021318509,"sku":"CSB-PA240615-50UL","price":170.98,"currency_code":"USD","in_stock":true},{"title":"100 uL","offer_id":53247123652973,"sku":"CSB-PA240615-100UL","price":307.97,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-PA240615-P.jpg?v=1776776265"},{"product_id":"eculizumab-biosimilar-research-grade-bha18300148","title":"Eculizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eEculizumab\u003c\/strong\u003e. Like the reference molecule, it binds complement component C5 and blocks its cleavage into C5a and C5b, inhibiting formation of the terminal complement complex (C5b-9). It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Eculizumab and therefore targets \u003cstrong\u003eComplement C5\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eComplement C5\u003c\/strong\u003e. The molecule binds complement component C5 and blocks its cleavage into C5a and C5b, inhibiting formation of the terminal complement complex (C5b-9).\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against Complement C5; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of Complement C5 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to Complement C5.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Eculizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eEculizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eComplement C5\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2\/4κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of Complement C5 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Eculizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327958704493,"sku":"ab-131-eculizumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_1e8e0070-9c44-4ed5-aee5-c78f459be7a5.jpg?v=1778728448"},{"product_id":"alemtuzumab-biosimilar-research-grade-bha18300145","title":"Alemtuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAlemtuzumab\u003c\/strong\u003e. Like the reference molecule, it binds CD52 on the surface of lymphocytes and mediates antibody-dependent cell lysis and lymphocyte depletion. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Alemtuzumab and therefore targets \u003cstrong\u003eCD52\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD52\u003c\/strong\u003e. The molecule binds CD52 on the surface of lymphocytes and mediates antibody-dependent cell lysis and lymphocyte depletion.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD52; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD52 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD52.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD52 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Alemtuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAlemtuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD52\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD52 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Alemtuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959425389,"sku":"ab-131-alemtuzumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_95fbfd0a-adb7-4c81-a451-c3fb6398886b.jpg?v=1778728442"},{"product_id":"bevacizumab-biosimilar-research-grade-bha18300146","title":"Bevacizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eBevacizumab\u003c\/strong\u003e. Like the reference molecule, it binds and neutralizes vascular endothelial growth factor A (VEGF-A), blocking VEGF receptor activation and angiogenesis. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Bevacizumab and therefore targets \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. The molecule binds and neutralizes vascular endothelial growth factor A (VEGF-A), blocking VEGF receptor activation and angiogenesis.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against VEGF-A; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of VEGF-A in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to VEGF-A.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Bevacizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eBevacizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eVEGF-A\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of VEGF-A binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Bevacizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959753069,"sku":"ab-131-bevacizumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_13863ba4-2f88-424a-b51e-d3e4e7757461.jpg?v=1778728442"},{"product_id":"infliximab-biosimilar-research-grade-bha18300149","title":"Infliximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eInfliximab\u003c\/strong\u003e. Like the reference molecule, it binds soluble and transmembrane TNF-α and neutralizes its pro-inflammatory signaling. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Infliximab and therefore targets \u003cstrong\u003eTNF-α\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α\u003c\/strong\u003e. The molecule binds soluble and transmembrane TNF-α and neutralizes its pro-inflammatory signaling.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Infliximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eInfliximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Infliximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959982445,"sku":"ab-131-infliximab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_799f3117-df0f-4a15-816c-18e38943fe50.jpg?v=1778728448"},{"product_id":"cetuximab-biosimilar-research-grade-bha18300147","title":"Cetuximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eCetuximab\u003c\/strong\u003e. Like the reference molecule, it binds the extracellular domain of EGFR and blocks ligand binding and receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Cetuximab and therefore targets \u003cstrong\u003eEGFR (HER1)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR (HER1)\u003c\/strong\u003e. The molecule binds the extracellular domain of EGFR and blocks ligand binding and receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR (HER1); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR (HER1) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR (HER1).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR (HER1) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Cetuximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eCetuximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR (HER1)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR (HER1) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Cetuximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327960375661,"sku":"ab-131-cetuximab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_17424d1a-f444-4b3a-bde5-ba01fa5a0ec4.jpg?v=1778728445"},{"product_id":"adalimumab-biosimilar-research-grade-bha18300144","title":"Adalimumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAdalimumab\u003c\/strong\u003e. Like the reference molecule, it binds and neutralizes soluble and transmembrane TNF-α. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Adalimumab and therefore targets \u003cstrong\u003eTNF-α\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α\u003c\/strong\u003e. The molecule binds and neutralizes soluble and transmembrane TNF-α.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Adalimumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAdalimumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Adalimumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327960768877,"sku":"ab-131-adalimumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_d2f19b4a-d227-4876-90b0-80bf02bb5dfc.jpg?v=1778728447"},{"product_id":"matuzumab-biosimilar-research-grade-bha18300150","title":"Matuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eMatuzumab\u003c\/strong\u003e. Like the reference molecule, it binds EGFR and blocks ligand-induced receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Matuzumab and therefore targets \u003cstrong\u003eEGFR\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR\u003c\/strong\u003e. The molecule binds EGFR and blocks ligand-induced receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Matuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eMatuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Matuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961489773,"sku":"ab-131-matuzumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_44d727ee-5250-4165-9a7c-949e8fac052e.jpg?v=1778728453"},{"product_id":"rituximab-biosimilar-research-grade-bha18300154","title":"Rituximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eRituximab\u003c\/strong\u003e. Like the reference molecule, it binds CD20 on B cells and triggers complement-dependent and antibody-dependent B-cell depletion. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Rituximab and therefore targets \u003cstrong\u003eCD20\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD20\u003c\/strong\u003e. The molecule binds CD20 on B cells and triggers complement-dependent and antibody-dependent B-cell depletion.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD20; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD20 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD20.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD20 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Rituximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eRituximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD20\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD20 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Rituximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961719149,"sku":"ab-131-rituximab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_62861a91-aeec-43f3-bf6f-3029db77c7b4.jpg?v=1778728454"},{"product_id":"avelumab-biosimilar-research-grade-bha18300160","title":"Avelumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAvelumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-L1 and blocks its interaction with PD-1; retains ADCC activity. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Avelumab and therefore targets \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. The molecule binds PD-L1 and blocks its interaction with PD-1; retains ADCC activity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-L1 (CD274); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-L1 (CD274) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-L1 (CD274).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-L1 (CD274) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Avelumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAvelumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-L1 (CD274)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1λ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-L1 (CD274) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Avelumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961817453,"sku":"ab-131-avelumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_3695d9fe-197e-45f0-8189-8532cb6828c4.jpg?v=1778728455"},{"product_id":"denosumab-biosimilar-research-grade-bha18300162","title":"Denosumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eDenosumab\u003c\/strong\u003e. Like the reference molecule, it binds RANKL and prevents RANK activation, inhibiting osteoclast differentiation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Denosumab and therefore targets \u003cstrong\u003eRANKL (TNFSF11)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eRANKL (TNFSF11)\u003c\/strong\u003e. The molecule binds RANKL and prevents RANK activation, inhibiting osteoclast differentiation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against RANKL (TNFSF11); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of RANKL (TNFSF11) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to RANKL (TNFSF11).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Denosumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eDenosumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eRANKL (TNFSF11)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of RANKL (TNFSF11) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Denosumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961784685,"sku":"ab-131-denosumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_fcc0126f-72f8-4697-9e3d-ee81f89538c1.jpg?v=1778728455"},{"product_id":"ipilimumab-biosimilar-research-grade-bha18300166","title":"Ipilimumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eIpilimumab\u003c\/strong\u003e. Like the reference molecule, it binds CTLA-4 and blocks its interaction with CD80\/CD86, enhancing T-cell activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ipilimumab and therefore targets \u003cstrong\u003eCTLA-4 (CD152)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCTLA-4 (CD152)\u003c\/strong\u003e. The molecule binds CTLA-4 and blocks its interaction with CD80\/CD86, enhancing T-cell activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CTLA-4 (CD152); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CTLA-4 (CD152) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CTLA-4 (CD152).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CTLA-4 (CD152) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ipilimumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eIpilimumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCTLA-4 (CD152)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CTLA-4 (CD152) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ipilimumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961882989,"sku":"ab-131-ipilimumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_6c85ec3e-60ca-4851-b6f8-72c9f77198a7.jpg?v=1778728456"},{"product_id":"nivolumab-biosimilar-research-grade-bha18300152","title":"Nivolumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eNivolumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell activity. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Nivolumab and therefore targets \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. The molecule binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell activity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-1 (CD279); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-1 (CD279) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-1 (CD279).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-1 (CD279) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Nivolumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eNivolumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-1 (CD279)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-1 (CD279) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Nivolumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961948525,"sku":"ab-131-nivolumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_cacb43e6-4d53-4d59-9d50-a45626148ed3.jpg?v=1778728452"},{"product_id":"tocilizumab-biosimilar-research-grade-bha18300155","title":"Tocilizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eTocilizumab\u003c\/strong\u003e. Like the reference molecule, it binds membrane-bound and soluble IL-6R and blocks IL-6 signaling. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Tocilizumab and therefore targets \u003cstrong\u003eIL-6 receptor (IL-6R)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eIL-6 receptor (IL-6R)\u003c\/strong\u003e. The molecule binds membrane-bound and soluble IL-6R and blocks IL-6 signaling.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against IL-6 receptor (IL-6R); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of IL-6 receptor (IL-6R) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to IL-6 receptor (IL-6R).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface IL-6 receptor (IL-6R) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Tocilizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eTocilizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eIL-6 receptor (IL-6R)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of IL-6 receptor (IL-6R) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Tocilizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961981293,"sku":"ab-131-tocilizumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_8da5eaea-ac36-48ef-b92f-f2277da3f4fb.jpg?v=1778728453"},{"product_id":"omalizumab-biosimilar-research-grade-bha18300153","title":"Omalizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eOmalizumab\u003c\/strong\u003e. Like the reference molecule, it binds the Cε3 domain of free human IgE and prevents IgE binding to the FcεRI receptor. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Omalizumab and therefore targets \u003cstrong\u003eHuman IgE (Cε3 domain)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHuman IgE (Cε3 domain)\u003c\/strong\u003e. The molecule binds the Cε3 domain of free human IgE and prevents IgE binding to the FcεRI receptor.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against Human IgE (Cε3 domain); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of Human IgE (Cε3 domain) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to Human IgE (Cε3 domain).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Omalizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eOmalizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHuman IgE (Cε3 domain)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of Human IgE (Cε3 domain) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Omalizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962014061,"sku":"ab-131-omalizumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_dfce8b46-4e57-46d6-9777-2b8e2b7753cc.jpg?v=1778728452"},{"product_id":"alirocumab-biosimilar-research-grade-bha18300159","title":"Alirocumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAlirocumab\u003c\/strong\u003e. Like the reference molecule, it binds PCSK9 and blocks its interaction with the LDL receptor. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Alirocumab and therefore targets \u003cstrong\u003ePCSK9\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePCSK9\u003c\/strong\u003e. The molecule binds PCSK9 and blocks its interaction with the LDL receptor.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PCSK9; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PCSK9 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PCSK9.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Alirocumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAlirocumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePCSK9\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PCSK9 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Alirocumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962046829,"sku":"ab-131-alirocumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_b2d9ad05-96d4-4000-99d7-5b0222458b1c.jpg?v=1778728455"},{"product_id":"pertuzumab-biosimilar-research-grade-bha18300171","title":"Pertuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003ePertuzumab\u003c\/strong\u003e. Like the reference molecule, it binds HER2 subdomain II and blocks HER2–HER3 heterodimerization. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Pertuzumab and therefore targets \u003cstrong\u003eHER2 (ERBB2), dimerization domain II\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHER2 (ERBB2), dimerization domain II\u003c\/strong\u003e. The molecule binds HER2 subdomain II and blocks HER2–HER3 heterodimerization.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against HER2 (ERBB2), dimerization domain II; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of HER2 (ERBB2), dimerization domain II in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to HER2 (ERBB2), dimerization domain II.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface HER2 (ERBB2), dimerization domain II on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Pertuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003ePertuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHER2 (ERBB2), dimerization domain II\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of HER2 (ERBB2), dimerization domain II binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Pertuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962079597,"sku":"ab-131-pertuzumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2810e90d-5831-4893-a7be-4159a897fa1b.jpg?v=1778728454"},{"product_id":"etanercept-biosimilar-research-grade-bha18300164","title":"Etanercept Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eFc-fusion protein\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis research-grade reagent reproduces the target specificity of the reference biologic \u003cstrong\u003eEtanercept\u003c\/strong\u003e. It is a soluble dimeric TNF receptor that binds and neutralizes TNF-α and lymphotoxin-α. Supplied for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional control and assay standard.\u003c\/p\u003e\n  \u003cp\u003e\u003cstrong\u003eEtanercept\u003c\/strong\u003e is a fusion protein, not a monoclonal antibody; this product is the corresponding recombinant Fc-fusion protein and is provided as a research-grade equivalent.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α \/ lymphotoxin-α\u003c\/strong\u003e. The molecule is a soluble dimeric TNF receptor that binds and neutralizes TNF-α and lymphotoxin-α.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α \/ lymphotoxin-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α \/ lymphotoxin-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α \/ lymphotoxin-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Etanercept.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eEtanercept\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eRecombinant Fc-fusion protein (TNFR2\/p75 ectodomain – human IgG1 Fc)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α \/ lymphotoxin-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003e— (not an antibody)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α \/ lymphotoxin-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Etanercept drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962112365,"sku":"ab-131-etanercept","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_ed2685ad-e353-4fd8-9104-9901c32a2803.jpg?v=1778728457"},{"product_id":"trastuzumab-biosimilar-research-grade-bha18300156","title":"Trastuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eTrastuzumab\u003c\/strong\u003e. Like the reference molecule, it binds HER2 subdomain IV, inhibits HER2 signaling and mediates ADCC. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Trastuzumab and therefore targets \u003cstrong\u003eHER2 (ERBB2), domain IV\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHER2 (ERBB2), domain IV\u003c\/strong\u003e. The molecule binds HER2 subdomain IV, inhibits HER2 signaling and mediates ADCC.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against HER2 (ERBB2), domain IV; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of HER2 (ERBB2), domain IV in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to HER2 (ERBB2), domain IV.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface HER2 (ERBB2), domain IV on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Trastuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eTrastuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHER2 (ERBB2), domain IV\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of HER2 (ERBB2), domain IV binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Trastuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962145133,"sku":"ab-131-trastuzumab","price":314.67,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2f322bc4-3373-45e8-9846-919978eeee36.jpg?v=1778728452"}],"url":"https:\/\/www.ebiohippo.com\/collections\/rc-drug-development-drug-immunogenicity.oembed?page=2","provider":"BioHippo","version":"1.0","type":"link"}